Eli Lilly CEO David Ricks' pay rose to almost $30 million in 2024
CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the ...
Eli Lilly wants to make drugs in America. First it wants a tax cut
Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, announced Wednesday that it plans to invest $27 ...
Eli Lilly's first weight loss pill could expand access to GLP-1s around the globe, executive says
Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.
Is Eli Lilly Stock a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
STAT2h
Altimmune to study obesity drug in alcohol use disorder, following Eli Lilly
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Eli Lilly plans to launch weight-loss drug in emerging markets this year
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...
Lilly, J&J boosted spending on executive security after UnitedHealth shooting
U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...
The Motley Fool3d
Is Eli Lilly Stock a Buy?
Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...